| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Myfembree | |
| 3 | Generic | relugolix, estradiol, norethindrone | |
| 4 | Economics | Myovant | |
| 5 | Indications | Uterine Fibroids, Endometriosis | |
| 6 | Regulatory | 4/2022 sNDA notice on endometriosis deficiencies | |
| 7 | Clinical Trials | ||
| 8 | Phase III LIBERTY | ||
| 9 | |||
| 10 | Phase III SPIRIT 1, SPIRIT 2 | ||
| 11 | 75% reduction in dysmenorrhea vs 27-30% at week 24 |